Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro.

Abstract

Carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine (Carbovir: NSC 614846), a novel nucleoside analog, emerged as a potent and selective anti-HIV agent from a large screening program conducted by the National Cancer Institute and its contractors. Its hydrolytic stability and its ability to inhibit the infectivity and replication of HIV in T-cells at concentrations of approximately 200- to 400-fold below toxic concentrations make carbovir a top-priority candidate for development as a potential antiretroviral agent in the treatment of AIDS patients.

• Authors: R Vince, M Hua, J Brownell, S Daluge, F C Lee, W M Shannon, G C Lavelle, J Qualls, O S Weislow, R Kiser
• Journal: Biochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 156 Issue 2 Pg. 1046-53 (Oct 31 1988) ISSN: 0006-291X [Print] United States
• PMID: 2847711 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antiviral Agents
• Dideoxynucleosides
• carbovir
• Zidovudine
• Zalcitabine

Topics

• Acquired Immunodeficiency Syndrome (drug therapy)
• Antiviral Agents
• Cytopathogenic Effect, Viral (drug effects)
• Dideoxynucleosides (pharmacology)
• HIV (drug effects, physiology)
• Molecular Structure
• Structure-Activity Relationship
• Virus Replication (drug effects)
• Zalcitabine
• Zidovudine (pharmacology)